✦ LIBER ✦

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer

✍ Scribed by Sumitra THONGPRASERT; Unchalee PERMSUWAN; Chidchanok RUENGORN; Chaiyut CHAROENTUM; Busyamas CHEWASKULYONG

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of paclitaxel plus ci

✍ Earle, C C; Evans, W K 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 84 KB

Randomised phase III trial of carboplati

✍ Okamoto, H; Watanabe, K; Kunikane, H; Yokoyama, A; Kudoh, S; Shibata, T; Kunitoh 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 130 KB

A phase II study of paclitaxel plus cisp

✍ Hiroshi Sakai; Shuichi Yoneda; Tomohide Tamura; Yutaka Nishiwaki; Akira Yokoyama 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 77 KB

Etoposide versus etoposide plus high-dos

✍ Professor Riccardo Rosso; Franco Salvati; Andrea Ardizzoni; Corrado Gallo Curcio 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 568 KB

A prospective, multicentre clinical tria

✍ Tuncay GOKSEL; Osman Nuri HATIPOGLU; Can OZTURK; Metin GORGUNER; Murat KIYIK; Ug 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Phase II trial of edatrexate plus carbop

✍ D. R. Gandara; Martin J. Edelman; John J. Crowley; Derick H. M. Lau; Robert B. L 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 130 KB